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Background: Antibiotic-associated diarrhoea (AAD) is a frequent complication of systemic
antibiotic therapy and Clostridium difficile-associated diarrhoea (CDAD) is its most serious
form due to associated morbidity and mortality.
Aim: This trial aimed to investigate whether the probiotic VSL#3 prevents AAD and CDAD in
average-risk hospital patients.
Methods: Adult hospital inpatients exposed to systemic antibiotics were recruited to this
multicentre, randomized, double-blind, placebo-controlled trial. One sachet of VSL#3 or
placebo was given twice daily for the length of the antibiotics course and for seven days
thereafter. Primary outcomes were AAD and CDAD.
Findings: Patients randomized to active (N ¼ 117) and placebo (N ¼ 112) groups were
well-matched for baseline demographic patient data. No cases of CDAD were detected.
The rate of AAD was significantly lower in the active group on per protocol analysis (0%
active vs 11.4% placebo; P ¼ 0.006). On intention-to-treat analysis the difference in AAD
incidence (4.3% active vs 8.9% placebo; P ¼ 0.19) was not significant.
Conclusions: VSL#3 is associated with a significant reduction in the incidence of AAD in
average-risk hospital inpatients exposed to systemic antibiotics. As the incidence of CDAD
has fallen sharply, no cases of CDAD were found. Probiotic administration as prophylaxis
for CDAD may not be indicated in average-risk hospital patients.
ª 2013 The Healthcare Infection Society. Published by Elsevier Ltd.
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Adverse drug events and nosocomial infections are among
the most frequent and potentially serious healthcare-related
complications. Systemic antibiotic therapy frequently causes
antibiotic-associated diarrhoea (AAD).1 Clostridium difficile-
associated diarrhoea (CDAD) e the most serious form of AAD e
is associated with significant morbidity and mortality.2,3 TheLtd. Open access under CC BY-NC-ND license.
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emergence of hypervirulent strains of bacteria associated with
increased mortality has been reported.4e6 In the UK a rapid rise
in CDAD incidence led to much media attention in 2008 and
subsequently strict government guidance aimed at reducing
CDAD.7
Whereas targeted antibiotic therapies with metronidazole
or oral vancomycin are moderately effective in treating CDAD,
prevention of CDAD is the best tactic to avoid the morbidity,
mortality and healthcare costs associated with CDAD. Identi-
fication of risk factors for CDAD allows detecting patients at
high risk. A number of risk factors for CDAD have been pro-
posed; only age, duration of hospital stay, previous CDAD and
antibiotic exposure were independent risk factors for the
development of CDAD.5 Other reported risk factors were
related to those variables.5 As these risk factors are mostly not
modifiable, they offer no target for intervention.
Prevention of AAD and CDAD by probiotic co-administration
during antibiotic exposure is an appealing concept. Probiotic
preparations are generally well tolerated and are seen posi-
tively by the general public.8 There is reasonably good evi-
dence that probiotic preparations (especially the strains
Saccharomyces boulardii or Lactobacillus spp.) can prevent
AAD in patients exposed to systemic antibiotics.1,9,10 The evi-
dence for CDAD preventions is, however, inconclusive as the
few published trials have shown conflicting results, and are not
applicable to the average-risk patient due to strict exclusion
criteria.11,12 This trial aimed to establish whether probiotic
preparations can prevent the occurrence of AAD and CDAD in
the average-risk hospital patient. To ensure that the study
findings are generally applicable, exclusion criteria were kept
to a minimum.Methods
Design
The primary study hypothesis was that the probiotic prep-
aration VSL#3 can prevent the occurrence of AAD and CDAD in
the average-risk adult hospital inpatient exposed to systemic
antibiotics. The occurrence of AAD and CDAD were the two co-
primary endpoints. For the purpose of this trial AAD was
defined as more than two liquid stools (Bristol stool chart types
6 and 7) in excess of normal for each patient a day for two or
more days.12 If a patient passed two or more stools of consis-
tency 6 or 7, a stool sample was sent for culture, microscopy
and C. difficile toxin A and B analysis. Toxin testing was per-
formed with Premier Toxin AþB (Meridian Bioscience, Cincin-
nati, OH, USA) at the Hull and Bristol sites and C. Diff Quick
Chek Complete (Techlab, Blacksburg, VA, USA) at the Weston
and Wigan sites. CDAD was defined as meeting the criteria for
AAD and a positive C. difficile toxin for A and/or B. Secondary
outcomes were the length of hospital stay and 30-day mortal-
ity. The background incidence of CDAD in the participating
hospitals was extracted from data provided by the Health
Protection Agency.13Participants
Adult inpatients receiving systemic antibiotics for infections
at four acute National Health Service (NHS) hospitals [RoyalAlbert Edward Infirmary (Wigan), North Bristol NHS Trust, Hull
Royal Infirmary, and Weston General Hospital] were eligible for
participation. Informed written consent was obtained from
competent individuals. The trial was permitted to recruit pa-
tients lacking capacity in accordance with section 30 of the
Mental Capacity Act 2005 provided next of kin agreed. Patients
having taken antibiotics within four weeks prior to admission,
patients on high-risk antibiotics, and patients with bowel pa-
thology (provided there was no diarrhoea on presentation)
were all eligible for participation. Patients were excluded from
participation if they were unable to take the study medication
(persistent vomiting, no enteral feeding possible, etc.),
required admission to an intensive care unit, had diarrhoea at
presentation (endpoint), suffered from acute pancreatitis
(adverse outcome data), had taken probiotic preparations
within a week of hospital admission (confounder) or were at
theoretical risk of probiotic-induced infection (severe immu-
nosuppression or risk for endocarditis). Antibiotic exposure was
classified as high risk in accordance with Dial et al. if the pa-
tient was exposed to multiple antibiotics or to a single antibi-
otic seen as high risk for CDAD (clindamycin, cephalosporins
and broad-spectrum penicillins).14
Intervention
The active group was allocated to receive the probiotic
preparation VSL#3 twice daily for the duration of the antibiotic
course and for a further seven days thereafter. The placebo
group received a similar-appearing placebo (containing
maltose and silicon oxide) in the same fashion, thus guaran-
teeing effective blinding of patients, nursing staff, medical
staff and all investigators. VSL#3 contains Bifidobacterium
breve, Bifidobacterium longum, Bifidobacterium infantis,
Lactobacillus acidophilus, Lactobacillus plantarum, Lactoba-
cillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus,
Streptococcus thermophilus in a concentration of 450 billion
live bacteria per sachet. VSL#3 was chosen as its content
closely matches the bacterial species and strains, which have
previously shown promise in the prevention of AAD and
CDAD.1,12 Furthermore VSL#3 has the highest concentration of
all commercially available probiotic preparations. The dosing
regimen was based on that of a pilot study in critically ill pa-
tients on intensive care units demonstrating that two sachets
of VSL#3 reduced the number of liquid stools.15 Adherence was
monitored using patient diaries and non-adherence was
defined as taking less than 80% of the prescribed doses.
Study plan
Potential participants were identified and approached by
the research nurses within 48 h of first hospital antibiotic
administration. After obtaining informed consent (or comple-
tion of the procedure for patients lacking capacity) baseline
data were recorded and participants were randomized by the
hospital pharmacy. The first study medication was adminis-
tered within 48 h of first hospital antibiotic administration.
Participants and ward nursing staff filled in the patient diary
and daily Bristol stool charts until the end of follow-up, which
occurred for 28 days after the last antibiotic dose. Those pa-
tients receiving repeat antibiotics within the 28-day follow-up
period were restarted on the study medication and 28-day
follow-up was again initiated after antibiotics were stopped.
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provided with the required amount of study medication, pa-
tient diaries, stool charts and stool specimen containers. The
research nurses then arranged for weekly telephone follow-up.
Sample size
Power and sample size calculations were based on the most
up-to-date AAD and CDAD incidence data at trial design pro-
vided by the trial from Hickson et al.12 Hence incidences of 30%
for AAD and 15% for CDAD were expected for the placebo group.
The investigators aimed to detect a 50% reduction in incidence
of AAD and, assuming a 10% drop-out, 389 patients were
needed to achieve 90% power using Fisher’s exact test and 5%
significance level. To detect a reduction in CDAD incidence
from 15% to 5%, 445 patients were required to achieve 90%
power. The trial was therefore powered for two co-primary
endpoints.
Randomization
Participants were randomized 1:1 to active or placebo group
using computer-generated random-permuted blocks stratified
by centre, which were supplied by an independent statistician.
Allocation of participants was performed by the pharmacies at
each site, which remained blinded throughout the trial.
Statistical analysis
To test the primary hypothesis that VSL#3 can prevent AAD
and CDAD, categorical outcome data were compared using
Fisher’s exact test and continuous variables were analysed
using Student’s t-test. Patients with poor adherence (<80%)
and those with major protocol breaches were excluded from
per protocol analysis. Intention-to-treat (ITT) analysis was
performed on the basis of the last observation carried forward.
Interim outcome and safety analyses were performed annually
using SPSS, Inc. (Chicago, IL, USA) software.
Study registration and approval
The study was approved by the Medicine and Healthcare
Products Regulatory Authority (EUDRACT: 2008-005244-16);
ethical approval was granted by the North Staffordshire Local
Research Ethics Committee (08/H1201/147); clinical trial
registration number: NCT00973908.
Results
In all, 3151 patients were screened for participation and 231
(7.3%) were recruited to the study from April 2010 to February
2012 (Figure 1). Major causes (Table I) for non-recruitment
were the patients’ unwillingness to participate (34.2%) and
patients feeling too unwell to consider participation (14.3%).
Only three of 353 screened patients lacking capacity were
recruited to the trial.
There were no differences in baseline patient data between
active and placebo groups (Table II). There was no difference in
high-risk antibiotic regimen exposure between the active and
placebo groups (82.1% vs 73.0%; P ¼ 0.74; Table III). Repeat
courses of systemic antibiotics were given to 26 (14 in theactive group) patients, of whom 12 received a repeat course of
active drug (seven patients) or placebo (five patients), while 14
were withdrawn from the trial. Non-adherence to the study
medication (40.2% vs 37.5%; P ¼ 0.69) and the proportion of
patients finishing the trial as per protocol (52.1% vs 54.4%;
P ¼ 0.79) did not differ between active and placebo groups.
Main protocol breaches were refusal to take the study medi-
cation (N ¼ 10), poor adherence (N ¼ 10), lost to follow-up
after discharge from hospital (N ¼ 12), patients becoming too
unwell (N¼ 11), and longer-term courses of antibiotics (N¼ 9).
The study medication was well tolerated and no drug-related
adverse events occurred (Table III). AAD occurred in 15 cases.
Six patients (four of them after hospital discharge), who
developed AAD, failed to provide stool specimens for analysis.
All cases of AAD were self-limiting and no cases of CDAD were
detected. There were no differences in adverse event rates
between active and placebo groups (Table IV).
The rate of AAD was significantly lower in the active group
on per protocol analysis [11.4% (seven cases) placebo vs no
cases active; P ¼ 0.006]. On ITT analysis the detected differ-
ence in AAD incidence [8.9% (10 cases) placebo vs 4.3% (five
cases) active; P ¼ 0.19] was not significant. A reduction in
length of hospital stay [6.7 (active) vs 8.7 (placebo) days;
P ¼ 0.09] on per protocol analysis was not significant (Table V).
The incidence of CDAD per 100,000 bed-days for the partici-
pating hospitals was 136.7 in 2007, 51.3 in 2008, 36.7 in 2009,
and 20.5 in 2010.
The trial was stopped prematurely on advice by the inde-
pendent data-monitoring committee as significance on the AAD
co-primary endpoint had been achieved. It was deemed futile
to continue the trial as the low incidence of CDAD made it very
unlikely that significance could be shown.Discussion
Nosocomial infections and especially CDAD pose a significant
risk to patients due to associated morbidity and mortality.
Prevention of CDAD has therefore become a key goal of UK
hospital policy and strict national monitoring has been imple-
mented.7 Prevention of CDAD by probiotic co-administration is
seen as an appealing concept, but the evidence is not robust
enough to recommend widespread prophylactic use.16 This
large, multicentre, double blind, randomized, placebo-
controlled trial aimed to establish whether prophylactic
administration of the probiotic preparation VSL#3 can prevent
the occurrence of AAD and CDAD in average-risk hospital in-
patients. The authors aimed to ensure general applicability of
the trial findings and deliberately set wide inclusion criteria; all
adult hospital patients on systemic antibiotics were eligible for
participation. Exclusion criteria were kept to a minimum
required for safety purposes. By contrast with previous trials,
patients with a history of gastrointestinal disease or previous
gastrointestinal surgery were included as these patients are
often seen as at higher risk of CDAD.12 More importantly pa-
tients on antibiotics putting them at high risk of CDAD were
specifically included, again by contrast with previous trials.12
Effective blinding of participants and staff was achieved and
the multicentre design incorporated a mixture of teaching and
district general hospitals. Recruitment proved difficult as
previously experienced by other investigators and only 7.3% of
screened patients were recruited.11,12 The majority of screen
117 Active 112 Placebo
56 withdrawn 
- 4 by doctor 
- 31 by patient 
- 21 other 
47 withdrawn 
- 8 by doctor 
- 24 by patient 
- 19 other 
Active 
61 completed trial in
accordance with
protocol   
Placebo
61 completed trial in
accordance with
protocol   
229 randomized
231 enrolled in trial
Screen failures
(see Table I) 
3151 screened for participation
1 withdrew before
randomization
1 randomization error   
Figure 1. Patient flow.
Table I
Screening results
Result Total
Recruited 231 (7.3%)
Vomiting or otherwise unable to take oral
medications
251 (8.0%)
Diarrhoea at screening 236 (7.5%)
Previous probiotic consumption 60 (1.9%)
Patients too unwell 452 (14.3%)
Acute pancreatitis 16 (0.5%)
Severely immunocompromised 84 (2.7%)
Risk of endocarditis 69 (2.2%)
No capacity to consent and no relative or
friend contactable
353 (11.2%)
Patient unwilling to participate 1079 (34.2%)
Others 320 (10.2%)
Total 3151 (100%)
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medical conditions requiring exclusion.
The effectiveness of VSL#3 in preventing AAD has been
demonstrated clearly by significance (P ¼ 0.006) on per pro-
tocol analysis. As a large number of protocol breaches were
due to poor adherence or complete refusal to take the study
medication, it is probably not surprising that the reduction of
AAD on ITT analysis (8.9% to 4.3%) was not of the same
magnitude and hence did not reach significance (P ¼ 0.19).
The study medication was well tolerated as adverse events
and protocol breaches were equally common in active and
placebo groups. Many protocol breaches were due to the
demanding nature of the study protocol on the patient (need
to keep stool charts, long courses of antibiotics and length of
follow-up) rather than the tolerability of VSL#3 or placebo.
Probiotic species and strains vary significantly between the
commercially available products, therefore the trial results
cannot be extrapolated to other probiotic products with
different species or strains, as demonstrated by a recent
Table II
Participants’ baseline data
Active
group
(N ¼ 117)
Placebo
group
(N ¼ 112)
P-value
Male 67 (57%) 53 (47%) 0.15a
Average age (years) 57.9 57.0 0.72b
Capacity to consent 116 (99%) 110 (98%) 0.62a
Dementia 0 2 (2%) 0.24a
Malignancy 6 (5%) 7 (6%) 0.78a
Cardiovascular disease 34 (29%) 25 (22%) 0.29a
Respiratory disease 45 (38%) 30 (27%) 0.07a
Immobility 13 (11%) 12 (11%) 1.0a
Hospital admission within
eight weeks prior to
enrolment
24 (21%) 27 (24%) 0.63a
Nursing or residential
home resident
0 3 (3%) 0.12a
Previous CDAD 2 (2%) 1 (1%) 1.0a
Proton pump inhibitor 32 (27%) 33 (29%) 0.77a
Antibiotics within four weeks
prior to enrolment
40 (34%) 44 (39%) 0.49a
Gastrointestinal disease 21 (18%) 24 (21%) 0.51a
Previous gastrointestinal
surgery
7 (6%) 10 (9%) 0.46a
CDAD, Clostridium difficile-associated diarrhoea.
a Fisher’s exact test.
b Student’s t-test.
Table IV
Adverse events
Active
group
(N ¼ 117)
Placebo
group
(N ¼ 112)
P-value
Non-serious adverse events 8 (6.8%) 10 (8.9%) 0.63a
Nausea 4 2
Abdominal pain 0 1
Heart burn 0 2
Pregnancy 0 1
Rash 0 1
Leg swelling 0 1
Tachycardia 0 1
Fall 0 1
Sore mouth 1 0
Pulmonary oedema 1 0
Nose bleed 1 0
Pleural effusion
Serious adverse events 6 (5.1%) 6 (5.4%) 1.0a
Hospital readmission 2 3
Same condition 2 2
Oesophageal bleed 0 1
Deaths 2 3
Pneumonia 1 1
Cancer 1 1
Pulmonary embolus 0 1
Prolonged hospital stay 2 0
Myocardial infarct 1 0
Severe diarrhoea and
vomiting
1 0
Suspected unexpected
serious adverse reaction
0 0 1.0a
a Fisher’s exact test.
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AAD.17
To judge the effectiveness of VSL#3 in preventing CDAD, a
minimum incidence is required. However, no cases of CDAD
were detected in this trial. The trial was designed and powered
in 2007, which coincided, as we now know, with the peak
incidence of CDAD in the UK. Department of Health guidance
has since led to considerable changes in infection control pol-
icy.7 Hand-wash policies were tightened, a ‘bare below theTable III
Antibiotic exposure
Active
group
(N ¼ 117)
Placebo
group
(N ¼ 112)
P-value
Median length of antibiotic
course in days
7 7 0.28a
Intravenous antibiotics 79 (67.5%) 78 (69.6%) 0.74b
High-risk antibiotic regimen 96 (82.1%) 89 (73.0%) 0.78b
Penicillins and broad-
spectrum penicillins
93 (79.5%) 84 (75.0%) 0.78b
Cephalosporins 4 (3.4%) 7 (6.3%) 0.36b
Quinolones 7 (6.0%) 4 (3.6%) 0.54b
Macrolides 28 (23.9%) 18 (16.1%) 0.19b
Aminoglycosides 15 (12.8%) 24 (20.3%) 0.11b
Imidazoles 8 (6.8%) 12 (10.7%) 0.35b
Others 15 (12.8%) 18 (16.1%) 0.57b
a ManneWhitney U-test.
b Fisher’s exact test.elbow’ policy was introduced for all clinical staff, isolation
efforts for infected patients intensified and antibiotic policies
were revised to reduce the use of high-risk antibiotics.7 Sub-
sequently the rate of CDAD infections per 100,000 bededays
fell sharply in the four participating hospitals from 136.7 in
2007 to 20.5 in 2010. Furthermore, the positive effects of the
‘cleanyourhands’ campaign on CDAD incidence have recently
been demonstrated at national level.18 The reduced CDAD
incidence in the participating centres rendered the original
power calculation incorrect and the trial was therefore tech-
nically underpowered to detect an effect on CDAD. Even if a
larger trial were to show an effect on CDAD incidence, the
effect would be small and the number needed to treat to
prevent one case of CDAD rather large. In light of such re-
ductions in background CDAD incidence and the findings of this
trial, probiotic prophylaxis to prevent CDAD in the average-risk
hospital patient appears not to be indicated. Such a measure
would not derive significant clinical benefit and would not be
cost-effective.
The reduction in AAD incidence was associated with a
shorter hospital stay, but this fell just short of significance. By
contrast with CDAD, AAD is rarely associated with considerable
morbidity and mortality. VSL#3 is efficacious in preventing AAD
in the average-risk hospital patient. In the absence of a clear
effect on hospital stay, it remains questionable whether
widespread AAD prophylaxis would be cost-effective.
Table V
Study outcomes
Intention to treat Per protocol
Active group
(N ¼ 117)
Placebo group
(N ¼ 112)
P Active group
(N ¼ 61)
Placebo group
(N ¼ 61)
P
AAD 5 (4.3) 10 (8.9%) 0.19 0 7 (11.4%) 0.006
CDAD 0 0 1.0 0 0 1.0
LOS (days) 8.6 8.5 0.96 6.7 8.7 0.09
30-day mortality 2 (1.7%) 4 (3.6%) 0.44 0 0 1.0
AAD, antibiotic-associated diarrhoea; CDAD, Clostridium difficile-associated diarrhoea; LOS, length of stay.
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tient, but high-risk patients could still benefit from prophy-
lactic probiotic administration. Recruiting very high-risk
patients to this trial proved difficult, but this is common in
CDAD prevention trials.11,12,17 Due to the lack of any CDAD
cases in this trial, the question whether VSL#3 can prevent
CDAD in principle remains unanswered. Patients at extremely
high risk of CDAD may benefit from probiotic preparations as
demonstrated by a reduction in CDAD (18.6% vs 5.8%, P ¼ 0.02)
in a randomized trial of 138 ventilated patients on an intensive
care unit.19 Hence there may be a role for probiotic prepara-
tions in high- and extremely high-risk patients. Furthermore
the risk of developing CDAD for average-risk patients may rise
during pandemics. Any effect of probiotic preparations in
preventing CDAD will therefore depend on the background
incidence of CDAD.Acknowledgements
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